

TAU 22809 (TAU 2022-54172)

AME Case Series Checklist –Adapted from CARE Checklist and PROCESS Checklist

Section	Item	Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title	1	The diagnosis or intervention of primary focus followed by the words "case series".	3, 39	methods/introduction, 5
Key Words	2	2 to 5 key words that identify diagnoses or interventions in this case series, including "case series".	1, 5	keywords, 1
Abstract	3a	Background-What is unique about this case series and what does it add to the scientific literature?	1, 11-12	introduction, 1
	3b	Case Presentation-What is the story of the patients, e.g., their medical history, clinical manifestations, diagnosis findings or challenges, therapies, outcomes, adverse/unanticipated events, and follow-ups?	4	case presentation, 2-6
	3c	Conclusions-What is the main take-away lesson(s)? What have we learned and what does it mean?	5, 18-20	conclusion, 1
Introduction	4	Explain the scientific background and rationale for the case series. What is the unifying theme - common disease, exposure, intervention and outcome, etc. Why is this study needed?	2, 37	introduction, 4
Methods	5a	Registration and ethics— 5a.1 State the research registry number in accordance with the declaration of Helsinki - "Every research study involving human subjects must be registered in a publicly accessible database" (this can be obtained from; ResearchRegistry.com or ClinicalTrials.gov or ISRCTN). 5a.2 State whether ethical approval was passed. 5a.3 Provide the patient consent form too.	2, 12	case presentation 1
	5b	Study design—state the study is a case series and whether prospective or retrospective in design, whether single or multi-center and whether cases are consecutive or non-consecutive.	3, 3-4	3
	5c	Setting - describe the setting(s) and nature of the institution in which the patient was managed; academic, community or private practice setting? Location(s), and relevant dates, including periods of recruitment, exposure, follow-up, and data collection.	3, 1	case presentation, multiple
	5d	Participants— 5d.1 Describe the relevant characteristics of the participants (history, comorbidities, tumor staging, smoking, etc.). 5d.2 State any eligibility (inclusion/exclusion) criteria and the sources and methods of selection of participants.	3, multiple	case presentation multiple
	5e	Intervention—types of intervention (such as pharmacologic, surgical, preventive, self-care) deployed and reasoning behind treatment offered. Pharmacological therapies should include formulation, dosage, strength, route and duration.	3 multiple	case presentation multiple
	5f	Follow up—describe length and methods of follow-up.	3 multiple	case presentation; multiple

Results	6a	Participants—reports numbers involved and their characteristics (comorbidities, tumor staging, smoking, etc.).	3, multiple	case presentation, milt. p. 2
	6b	Any changes in the interventions during the course of the case series (how has it evolved, been tinkered with, what learning occurred, etc.) together with rationale and a diagram if appropriate.	3	
	6c	Outcomes and follow-up—Clinician assessed and patient-reported outcomes (when appropriate) should be stated with inclusion of the time periods at which assessed. Relevant photographs/radiological images should be provided. e.g. 12-month follow-up.	3	
	6d	Where relevant—intervention adherence/compliance and tolerability (how was this assessed). Describe loss to follow-up (express as a percentage) and any explanations for it.	3	
	6e	Complications and adverse or unanticipated events.	3	
Discussion	7a	Summarize key results.	4, 9	discussion, 1
	7b	Discussion of the relevant literature, implications for clinical practice guidelines. How do outcomes compare with established therapies and the prevailing gold standard? Generate a hypothesis if possible.	pp 4-5	discussion, all
	7c	Strengths and limitations of the study.	p 5, 4	discussion, 4
	7d	The rationale for any conclusions.	p 5, 11	discussion, 4
Conclusion	8a	State the key conclusions from the study.	p 5, 11	conclusion, 1
	8b	State what needs to be done next, further research with what study design.	p 5, 19	conclusion,

Article information: <https://dx.doi.org/10.21037/tau-22-809>

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.